Brought to you by 
Cubist licenses IHMA's oral ceftriaxone
Dec 2000
Executive Summary
Cubist Pharmaceuticals has licensed exclusive worldwide rights to develop an oral version of CRO and intellectual property broker International Health Management Associates' antibiotic ceftriaxone.
Deal Industry
- Biotechnology
- Contract Research, Toxicology Testing-CRO
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist licenses IHMA's oral ceftriaxone
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice